Robert is the Vice President, Head of Corporate Development at Mestag Therapeutics, a preclinical stage biotech company harnessing new insights into fibroblast-immune biology to develop therapies for patients with cancer and auto-immune disease. Previously he was the Head of Business Development at Tusk Therapeutics, an immuno-oncology company developing first in class antibodies which was acquired by Roche in the preclinical stages in 2018. After the acquisition, he served as the CEO of Black Belt Tx (now Alesta Therapeutics), a discovery stage oncology company focused on targeting the stress response pathways in cancer. He was Head of Contract Research for reMYND, a biotech focused on Alzheimer’s, Parkinson’s and diabetes, and worked as an investment analyst at Merck Serono Ventures (now M Ventures), Merck KGaA’s corporate venture capital arm. He holds an MSc in molecular biology and business economics from Leiden University and Delft University of Technology.